SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 2/9/2016 1:46:11 PM - Followers: 186 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
Wiki
RNN News: Statement of Changes in Beneficial Ownership (4) 02/01/2016 04:36:36 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 02/01/2016 04:35:21 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 02/01/2016 04:34:00 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 02/01/2016 04:33:13 PM
RNN News: Amended Statement of Ownership (sc 13g/a) 01/19/2016 04:06:16 PM
PostSubject
#3035   Thanks Theo, finally some news...and it's good! gr8f1 02/09/16 01:46:10 PM
#3034   finance.yahoo.com/news/rexahn-pharmaceuticals-completes-stage-1-140000048.h Theo 02/08/16 09:23:54 AM
#3033   Is anyone buying rnn? Any good news Imoutpickinyou 01/27/16 01:56:59 PM
#3032   Agreed, and my apologies on that. I had Spideyboy 12/01/15 08:40:48 AM
#3031   RNN is traded on the NYSE and as DesertBlizzard 12/01/15 12:54:07 AM
#3030   I totally agree with your post. Spideyboy 11/30/15 10:00:06 AM
#3029   You are welcome! Dionna 11/30/15 09:52:21 AM
#3028   Hi Dionna, Spideyboy 11/30/15 09:46:36 AM
#3027   I've been here for over a year and Dionna 11/30/15 08:57:06 AM
#3026   Well cool ,i bailed months ago at 69 Spuds McKenz66 11/29/15 05:52:43 AM
#3025   Hi All, Spideyboy 11/21/15 12:44:56 PM
#3024   New Direct Offering for RNN,..... $7 MM via drkazmd65 11/06/15 09:21:11 AM
#3022   How long can she go? before long kpisme 10/22/15 05:15:45 PM
#3021   Rnn has huge potential but the reverse split chrisgold 10/07/15 09:14:05 AM
#3020   Thanks for your input, I've been in it Dionna 10/01/15 09:46:59 AM
#3019   Am still in the early stages of figuring drkazmd65 09/30/15 01:01:22 PM
#3018   Can anyone give any insight to what's really Dionna 09/30/15 11:48:00 AM
#3017   Good article from yesterday on Seeking Alpha,.... further drkazmd65 09/30/15 11:28:38 AM
#3016   My order never filled yesterday..trying again this morning RedPig 09/30/15 08:55:59 AM
#3015   added .50's, sit an wait now! harry crumb 09/29/15 03:45:27 PM
#3014   Yes sir! RedPig 09/29/15 09:29:11 AM
#3013   could be a profit maker today at .51! harry crumb 09/29/15 08:26:52 AM
#3012   $RNN recent news/filings stocktrademan 09/25/15 12:32:34 PM
#3011   Looking good here! RedPig 09/21/15 09:57:55 AM
#3010   Mod. Please delete. thealias2002 08/26/15 07:42:16 AM
#3009   Mod, please delete thealias2002 08/26/15 07:41:42 AM
#3008   Also, Laidlaw reiterated 3.00 per share,,,, and Roth 220v 08/13/15 12:27:33 PM
#3007   MLV analyst Vernon Bernardino reiterated a Buy rating 220v 08/13/15 11:09:09 AM
#3006   biz.yahoo.com/e/150807/rnn10-q.html Form 10-Q for REXAHN PHARMACE Theo 08/07/15 06:31:16 PM
#3005   This is a good entry price. NathanH 07/29/15 04:12:09 PM
#3004   Seems like RNN is fiscally responsible as well. 220v 07/18/15 08:33:22 PM
#3003   Checked their building, definitely in a good spot, BizotheGreat 07/15/15 04:51:57 PM
#3002   Positive news at below avg prices, I expect BizotheGreat 07/15/15 04:50:26 PM
#3001   Another case of sell the news, wait for Woulfe 07/15/15 03:51:29 PM
#3000   #RNN Just crossed SMA, Reversal in progress BizotheGreat 07/15/15 10:41:38 AM
#2999   #rnn big board stock with huge upside, drug BizotheGreat 07/15/15 09:26:13 AM
#2998   Cancer Drug Patent, RNN up 11% buy the dip BizotheGreat 07/14/15 10:13:48 AM
#2997   NEWS, patent approved ready to run BizotheGreat 07/14/15 09:43:45 AM
#2996   I agree Woulfe 07/10/15 04:09:41 PM
#2995   Stay the course! ...or buy more at 220v 07/10/15 11:12:12 AM
#2994   Possible Takeover Buyout from big pharma company always 220v 06/27/15 09:40:43 AM
#2993   , thanx for the info Fibanotch 06/21/15 07:34:05 PM
#2992   I didnt know I thought they were just NathanH 06/06/15 03:45:14 PM
#2991   Exactly. Thank you for the full in! thealias2002 06/06/15 03:09:48 PM
#2990   he meant, they approved an r/s last Updated 06/06/15 12:05:49 PM
#2989   How is it old if they just approved NathanH 06/06/15 10:24:21 AM
#2988   That's very old news. Multiple PPS drivers thealias2002 06/06/15 08:00:51 AM
#2987   Reduction in authorized stock and a 1:2-1:10 reverse NathanH 06/05/15 10:37:44 PM
#2986   Stagnation NathanH 06/05/15 10:36:48 AM
#2985   What's going on here? ThatsThe1 06/04/15 03:10:16 PM
PostSubject